ATRICURE INC (ATRC)

US04963C2098 - Common Stock

35.735  +0.05 (+0.15%)

After market: 35.735 0 (0%)

Fundamental Rating

3

Taking everything into account, ATRC scores 3 out of 10 in our fundamental rating. ATRC was compared to 188 industry peers in the Health Care Equipment & Supplies industry. ATRC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATRC is quite expensive at the moment. It does show a decent growth rate.



2

1. Profitability

1.1 Basic Checks

In the past year ATRC has reported negative net income.
In the past year ATRC had a positive cash flow from operations.
In the past 5 years ATRC reported 4 times negative net income.
ATRC had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -6.33%, ATRC is doing good in the industry, outperforming 62.03% of the companies in the same industry.
With a decent Return On Equity value of -8.37%, ATRC is doing good in the industry, outperforming 64.71% of the companies in the same industry.
Industry RankSector Rank
ROA -6.33%
ROE -8.37%
ROIC N/A
ROA(3y)-1.58%
ROA(5y)-3.56%
ROE(3y)-2.11%
ROE(5y)-6.45%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 74.79%, ATRC belongs to the top of the industry, outperforming 86.10% of the companies in the same industry.
In the last couple of years the Gross Margin of ATRC has remained more or less at the same level.
ATRC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y0.61%

5

2. Health

2.1 Basic Checks

ATRC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATRC has been increased compared to 1 year ago.
Compared to 5 years ago, ATRC has more shares outstanding
The debt/assets ratio for ATRC has been reduced compared to a year ago.

2.2 Solvency

ATRC has an Altman-Z score of 7.00. This indicates that ATRC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.00, ATRC belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
ATRC has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
ATRC's Debt to Equity ratio of 0.13 is in line compared to the rest of the industry. ATRC outperforms 54.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 7
ROIC/WACCN/A
WACC9%

2.3 Liquidity

A Current Ratio of 3.62 indicates that ATRC has no problem at all paying its short term obligations.
ATRC's Current ratio of 3.62 is fine compared to the rest of the industry. ATRC outperforms 61.50% of its industry peers.
ATRC has a Quick Ratio of 2.59. This indicates that ATRC is financially healthy and has no problem in meeting its short term obligations.
ATRC has a Quick ratio of 2.59. This is comparable to the rest of the industry: ATRC outperforms 58.29% of its industry peers.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 2.59

5

3. Growth

3.1 Past

The earnings per share for ATRC have decreased strongly by -31.75% in the last year.
Looking at the last year, ATRC shows a quite strong growth in Revenue. The Revenue has grown by 17.57% in the last year.
The Revenue has been growing by 14.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-31.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)17.57%
Revenue growth 3Y24.58%
Revenue growth 5Y14.64%
Sales Q2Q%17.93%

3.2 Future

ATRC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.33% yearly.
The Revenue is expected to grow by 16.70% on average over the next years. This is quite good.
EPS Next Y-15.12%
EPS Next 2Y6.71%
EPS Next 3Y12.32%
EPS Next 5Y9.33%
Revenue Next Year16.27%
Revenue Next 2Y14.84%
Revenue Next 3Y14.13%
Revenue Next 5Y16.7%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATRC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATRC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ATRC's earnings are expected to grow with 12.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.71%
EPS Next 3Y12.32%

0

5. Dividend

5.1 Amount

No dividends for ATRC!.
Industry RankSector Rank
Dividend Yield N/A

ATRICURE INC

NASDAQ:ATRC (11/22/2024, 4:38:47 PM)

After market: 35.735 0 (0%)

35.735

+0.05 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.74B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.33%
ROE -8.37%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 74.79%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.62
Quick Ratio 2.59
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-31.75%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-15.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)17.57%
Revenue growth 3Y24.58%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y